Medication info
Lozadin Plus Tablet

Lozadin Plus Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Eden Pharma Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 202000847 · Approved 2020.02.12 · Insurance code 628901580

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect is achieved after approximately 3 weeks of treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, initiate treatment with this medicine only when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: Treatment with separately titrated losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Thereafter, the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg should be monitored continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or greater. Use in patients with more severe renal impairment is not recommended, as loop diuretics are preferable to thiazide-type drugs in these patients. ○ Patients with hepatic impairment Use in these patients is not recommended because this medicine cannot provide the 25 mg initial dose of losartan potassium required for patients with hepatic impairment who need dose adjustment.
Child dose
Children (under 18 years): The losartan-hydrochlorothiazide combination should not be administered to children or adolescents because there is no experience with its use in this population.

Ingredients

Manufacturer
Eden Pharma Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for patients with hypertension who have difficulty controlling blood pressure with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect is achieved after approximately 3 weeks of treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, initiate treatment with this medicine only when the expected effect has not been achieved with monotherapy. 1. Replacement therapy: Treatment with separately titrated losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Thereafter, the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg should be monitored continuously. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or greater. Use in patients with more severe renal impairment is not recommended, as loop diuretics are preferable to thiazide-type drugs in these patients. ○ Patients with hepatic impairment Use in these patients is not recommended because this medicine cannot provide the 25 mg initial dose of losartan potassium required for patients with hepatic impairment who need dose adjustment.

Child dose

Children (under 18 years): The losartan-hydrochlorothiazide combination should not be administered to children or adolescents because there is no experience with its use in this population.

Precautions

This medication can cause severe harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This drug should not be administered to patients with certain diseases or conditions. For example, patients with severely impaired renal function or a history of specific allergies should not take this medication. Patients with very low blood pressure or those with renal or liver dysfunction should use this drug cautiously and consult healthcare professionals for proper management. This medication can cause electrolyte imbalances, so regular blood tests should be conducted to monitor electrolyte status, and any unusual symptoms should be reported immediately. Hydrochlorothiazide can make the skin sensitive to sunlight and increase the risk of skin cancer, so sun protection and skin care should be prioritized while taking it. Dizziness or drowsiness may occur during the use of this drug, so caution is needed when driving or operating machinery. There may be interactions with other medications, so all medications being taken should be disclosed to healthcare professionals, especially potassium supplements or certain diuretics to avoid concomitant use. Women who are breastfeeding should discontinue either breastfeeding or this medication, as it may be transmitted through breast milk and affect the baby. Safety and efficacy in children and adolescents have not been established, so this medication should not be used in pediatric populations. Elderly patients may experience side effects more frequently, so careful monitoring is required during use. In case of overdose, symptoms may include hypotension and arrhythmias, so immediate medical attention is required for appropriate treatment. This medication should be kept out of reach of children and stored in its original container to prevent misuse or degradation of quality.

Side effects

  • Abdominal pain
  • edema
  • palpitations
  • low back pain
  • dizziness
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
Show 125 more
  • skin peeling phenomenon
  • hemolysis
  • chest pain
  • facial swelling
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • joint pain
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • nervous hyperactivity
  • panic disorder
  • sensory abnormality
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremors
  • shortness of breath
  • nasal bleeding
  • nasal congestion
  • throat discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechial hemorrhage
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste disturbance
  • tinnitus
  • erectile dysfunction
  • nocturnal enuresis
  • frequency of urination
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • cramps
  • gastric irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle cramps
  • restlessness
  • renal failure
  • renal impairment
  • interstitial nephritis
  • mucocutaneous syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • yellow vision
  • acute myopia
  • acute closed-angle glaucoma
  • choroidal effusion
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vessel edema
  • dry cough
  • erythema
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a tightly sealed container that blocks light. The storage temperature should be maintained at room temperature between 1°C and 30°C. Storing it this way helps maintain the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.